Osmina
Composition
Osmina Tablet: Each film coated tablet contains Ospemifene INN 60 mg.
Indication
Osmina is an estrogen agonist/antagonist indicated for the treatment of moderate to severe
dyspareunia & vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause.
Dosage & Administration
Osmina is an estrogen agonist/antagonist which has agonistic effects on the endometrium. Use of
Osmina should be for the shortest duration consistent with treatment goals and risks for the individual
women.
One tablet should be taken orally once daily with food or as directed by the physician.
Olmepin
Composition
OlmepinTM 20/5 Tablet:Each film coated tablet contains Olmesartan Medoxomil USP 20 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.
Olmepin TM 40/5 Tablet:Each film coated tablet contains Olmesartan Medoxomil USP 40 mg & Amlodipine Besilate BP equivalent to Amlodipine 5 mg.
Indication
OlmepinTM is indicated for the treatment of hypertension, alone or with other antihypertensive agents. OlmepinTM may also be used as initial therapy in patients
who are likely to need multiple antihypertensive agents to achieve their blood pressure goals.
Dose & Administration
Initial Therapy: The usual starting dose of Olmesartan Medoxomil/Amlodipine Besilate is 20/5 mg one tablet once daily. The dosage can be increased after 1 to 2 weeks of
therapy to a maximum dose of 40/10 mg once daily as needed to control blood pressure. This combination may be taken with or without food. This combination may
be administered with other antihypertensive agents. Initial therapy with this combination products is not recommended in patients >75
years old or with hepatic impairment. Replacement therapy: Olmesartan Medoxomil/Amlodipine Besilate may be substituted for its individually titrated components. When substituting for individual components,
the dose of one or both of the components can be increased if blood pressure control has not been satisfactory.
Add-on Therapy: Olmesartan Medoxomil/Amlodipine Besilate may be used to provide additional blood pressure lowering for patients not adequately controlled with
Amlodipine (or another dihydropyridine Calcium Channel Blocker) alone or with Olmesartan Medoxomil (or another angiotensin II receptor blocker) alone Or as
directed by the physician
Orc
Composition:
OrcTM Tablet: Each film coated tablet contains Ketorolac Tromethamine USP 10 mg.
OrcTM 30 IV/IM injection: Each 1 ml ampoule contains Ketorolac Tromethamine USP 30 mg.
OrcTM 60 IV/IM injection: Each 2 ml ampoule contains Ketorolac Tromethamine USP 60 mg.
Indication:
OrcTM tablets are indicated for short term management of moderate postoperative pain and acute & chronic musculoskeletal pain as a continuation of treatment.
OrcTM injections are indicated for short term management of moderate to serve acute post-operative pain.
Dose & Administration:
OrcTM tablets: Ketorolac Tromethamine 10 mg tablet 4-6 hourly; Elderly 6-8 hourly. Maximum dose is 40 mg daily.
OrcTM Injection: Adult patient (<65 years): Ketorolac Tromethamine is for administration by intramuscular or intravenous injection. Initial dose is 60 mg IM or 30 mg IV. Maintenance dose is 30 mg IM/IV 6 hourly.
Ometac 20 Capsule
Composition
Ometac™ 20: Each capsule contains Omeprazole BP 20 mg.
Indications:
It is used for the treatment of oesophageal reflux disease, duodenal and benign gastric ulcer including those complicating NSAID therapy, Zollinger Ellison syndrome.
Dose & Administration:
Reflux Oesophagitis : The usual dose is 20 mg once daily for 4 weeks. For those patients not fully healed after the initial course ,a further 4-8 weeks treatment may require. Or as directed by the physician.
Odafen
Composition:
Odafen™ 120: Each film coated tablet contains Fexofenadine
Hydrochloride USP 120 mg.
Odafen™ 180: Each film coated tablet contains Fexofenadine
Hydrochloride USP 180 mg.
Odafen™ Suspension: Each 5 ml suspension contains Fexofenadine Hydrochloride USP 30 mg.
Indication:
Seasonal Allergic Rhinitis:
Odafen™ tablet are indicated for the relief of symptoms
associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Odafen™ oral suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years of age. Symptoms to treat
effectively:
sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes.
Chronic Idiopathic Urticaria:
Odafen™ of Chronic Idiopathic Urticaria in adults and children 6 years of age and
older.
Odafen™ manifestations of Chronic Idiopathic Urticaria in children 6 months to 11 years
of age. Fexofenadine Hydrochloride significantly reduces pruritus and the number
of wheals.